Business · 1 sources covering this

How Cardiologists’ High Hopes for Two Drugs Were Dashed

By every measure, the drugs were no better than placebos, full data revealed on Saturday. Was it the fault of the design of the studies, or our very hypotheses about heart disease?

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

New York TimesLean L·54m ago
How Cardiologists’ High Hopes for Two Drugs Were Dashed
By every measure, the drugs were no better than placebos, full data revealed on Saturday. Was it the fault of the design of the studies, or our very hypotheses about heart disease?
Read at New York Times →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/cacb3ae98b1db5c25b5b56b89bb78d4400311f76"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="How Cardiologists’ High Hopes for Two Drugs Were Dashed"></iframe>

How Cardiologists’ High Hopes for Two Drugs Were Dashed

How 1 sources are covering this

How Cardiologists’ High Hopes for Two Drugs Were Dashed

More from Business

31-year-old dumpster diver brought in $140,000 in 12 months: I 'did much more than I thought was possible'

Berkshire shares surge as Wall Street swoons amid AI fears

Mark Cuban says he doesn’t ‘give a f---' about growing his net worth—a healthy mindset for non-billionaires too, a financial therapist says

Berkshire Hathaway more than doubles buybacks in third quarter as earnings decline

Reader

Trust & legal

Across the network